RespiratorySanofi
Sanofi and Regeneron Report Phase 3 LIBERTY ASTHMA QUEST Results for Dupixent in Asthma
BMI
Biotechnology Media Insights
Editorial Team · December 8, 2023
Sanofi and Regeneron announce Phase 3 LIBERTY ASTHMA QUEST trial results showing Dupixent significantly reduces asthma exacerbations in moderate-to-severe asthma.
Sanofi and Regeneron today announced results from the Phase 3 LIBERTY ASTHMA QUEST trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe asthma. The trial met its primary endpoint, demonstrating a significant reduction in annualized asthma exacerbation rates compared to placebo. Dupixent also significantly improved lung function and asthma control.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.